
 
 
 
 
 
 
 
 
   
 1. Thermolabile enzyme with uracil-DNA-glycosylase activity obtained from microorganisms of the genus Arthrobacter or Micrococcus having a degree of purity of at least 95% (SDS gel) and half-lives of less than 5 minutes at about 40 0 C and of less than 2 minutes at about 45 0 C. 
 
     
 2. Enzyme as claimed in claim 1, wherein the content of contaminating foreign activities is less than 2% and the specific activity is at least 5 x 10 4 U/mg protein. 
 
     
 3. Enzyme as claimed in claim 1 or 2, wherein the temperature optimum is about 37°C and the pH optimum is about  
 
     
 4. Enzyme as claimed in one of the claims 1, 2 or 3, wherein the enzyme is isolated from the strain DSM 10239. 
 
     
 5. Stabilized solution of the thermolabile enzyme with uracil-DNA-glycosylase activity as claimed in claim 1 to 4, wherein the enzyme is contained in a mixture composed of 10 to 250 mM of a substance buffering in a weak alkaline range, 0.1 to 5mM of a complexing 20 agent, 0.5 to 5mM of an agent stabilizing SH groups, at least 100 mM sodium chloride, to 55% glycerol and optionally 0.1 to 5.0 mg/ml bovine serum albumin. S 
 
     
 6. Stabilized enzyme solution as claimed in claim 5, wherein it contains about 50 mM Hepes/KOH, pH 8.0, about 1 mM EDTA, about 1 mM dithiothreitol, about 300 mM sodium chloride and about 50% glycerol. 
 
     
 7. Process for the isolation of an enzyme as claimed in one of the claims 1 to 4 from gram-positive microorganisms, wherein after disruption of the cells and separating the DNA, a hydroxyapatite chromatography, an anion exchange chromatography and a hydrophobic chromatography are carried out. P:\OPER\VPA\11761-97.RSI 10/3/00 -23- 
 
     
 8. Process as claimed in claim 7, wherein DNA is separated by means of Polymin precipitation. 
 
     
 9. Process as claimed in claim 7 or 8, wherein the anion exchange chromatography is carried out on Q-Sepharose ff (high load). Process as claimed in claim 7, 8 or 9, wherein the hydrophobic chromatographic step is carried out on phenl Sepharose ff. 
 
     
 11. Process as claimed in claim 7, 8, 9 or 10, wherein the gram-positive microorganism DSM 10239 is used. 
 
     
 12. Use of a thermolabile enzyme with uracil-DNA-glycosylase activity as claimed in one of the claims 1 to 6 to detect DNA containing uracil or to remove the base uracil from DNA, S 15 wherein a mixture containing DNA containing uracil is incubated with the enzyme for about one minute to 30 minutes at a temperature of about 10 0 C and heated for about 1 to minutes to ca. 95 0 C. 
 
     
 13. Use as claimed in claim 12, wherein the DNA containing uracil is a specifically 20 amplified DNA. 0*0* 
 
     
 14. Use as claimed in claim 12 or 13, wherein when incubated between about 30 seconds and four hours at about 4°C uracil-DNA-glycosylase activity can no longer be detected. 
 
     
 15. Kit for amplifying specific nucleic acids or corresponding fragments, wherein it contains the following components: a thermolabile enzyme as claimed in one of the claims 1 to 4 in a suitable storage buffer, the nucleotide triphosphates dATP, dCTP, dGTP and dUTP, a thermostable DNA polymerase and P:\OPER\VPA\11761-97.RSI 1413100 -24- 
 
     
 16. Kit as claimed in claim 15, wherein the thermolabile enzyme is present at a concentration of about 0.1 to 5.0 U/ 1. 
 
     
 17. Kit as claimed in claim 15 or 16, wherein each of the nucleotide triphosphates dATP, dCTP and dGTP are at about a third of the concentration of dUTP. 
 
     
 18. Kit as claimed in one of the claims 15 to 17, wherein about 2 to 10 U/pl (final concentration) of the thermostable DNA polymerase is present. 
 
     
 19. Kit as claimed in one of the claims 15 to 19, wherein the reaction buffer additionally contains about 10 to 100 mM potassium chloride and/or about 1.0 to 5.0 mM magnesium chloride. 
 
     
 20. The thermostable enzyme of any one of claims 1 to 4, substantially as described herein 15 with reference to the Figures and/or Examples. 
 
     
 21. The stabilised solution of claim 5 or claim 6,substantially as described herein with reference to the Figures and/or Examples. 20 22, The process of any one of claims 7 to 11,substantially as described herein with reference to the Figures and/or Examples. a 
 
     
 23. The use of any one of claim 12 to 14,substantially as described herein with reference to the Figures and/or Examples. P:\OPER\VPA\11761-97.RS1 14/3/00 25  
 
     
 24. The kit of any one of claims 15 to 19, substantially as described herein with reference to the Figures and/or Examples. DATED this 14th day of March, 2000 Roche Diagnostics GmbH By DAVIES COLLISON CAVE Patent Attorneys for the applicant(s) *%.Poo 
 
   
 
 
 
 
 
 
 
 
